Showing results (221-230 of 242) with videos related to
Sort By:
Pageof 25
JCI Insight|October 5, 2016
PRL3-zumab, a first-in-class humanized antibody for cancer therapyMin Thura, Abdul Qader Omer Al-Aidaroos, Wei Peng Yong, et al.Journal of Translational Medicine|April 19, 2015
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenibAndrea Li Ann Wong, Joline Si Jing Lim, Arvind Sinha, et al.Oncotarget|September 1, 2016
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancerAndrea L A Wong, Raghav Sundar, Ting-Ting Wang, et al.The New England Journal of Medicine|October 17, 2025
Sevabertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung CancerXiuning Le, Tae Min Kim, Herbert H Loong, et al.Proceedings of the National Academy of Sciences of the United States of America|May 17, 2018
Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastomaLiang Xu, Ye Chen, Anand Mayakonda, et al.The Journal of Clinical Investigation|September 26, 2023
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignanciesStephen Jun Fei Chong, Fen Zhu, Olga Dashevsky, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2020
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive CancersSoo-Chin Lee, Noriko Shimasaki, Joline S J Lim, et al.Cell|April 12, 2024
A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2Li Ren Kong, Komal Gupta, Andy Jialun Wu, et al.Theranostics|June 30, 2025
Combination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancersCao Dai Phung, Trinh T T Tran, Brendon Zhi Jie Yeo, et al.Nature Communications|March 28, 2020
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinomaLi Ren Kong, Nur Afiqah Binte Mohamed Salleh, Richard Weijie Ong, et al.Pageof 25